Edgewise Therapeutics (EWTX) Competitors $14.80 +0.18 (+1.22%) Closing price 03:59 PM EasternExtended Trading$14.85 +0.05 (+0.34%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. NUVL, ABVX, AXSM, CRSP, MRUS, VKTX, TGTX, ACAD, CYTK, and AKROShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Nuvalent (NUVL), Abivax (ABVX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Merus (MRUS), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Its Competitors Nuvalent Abivax Axsome Therapeutics CRISPR Therapeutics Merus Viking Therapeutics TG Therapeutics ACADIA Pharmaceuticals Cytokinetics Akero Therapeutics Edgewise Therapeutics (NASDAQ:EWTX) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Does the media refer more to EWTX or NUVL? In the previous week, Edgewise Therapeutics had 1 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Edgewise Therapeutics and 11 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.83 beat Edgewise Therapeutics' score of 0.31 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Is EWTX or NUVL more profitable? Edgewise Therapeutics' return on equity of -30.65% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -30.65% -29.18% Nuvalent N/A -32.58%-30.14% Which has stronger earnings and valuation, EWTX or NUVL? Nuvalent is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-9.55NuvalentN/AN/A-$260.76M-$4.90-15.54 Which has more volatility and risk, EWTX or NUVL? Edgewise Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Do analysts recommend EWTX or NUVL? Edgewise Therapeutics presently has a consensus price target of $40.55, suggesting a potential upside of 173.97%. Nuvalent has a consensus price target of $118.91, suggesting a potential upside of 56.19%. Given Edgewise Therapeutics' higher probable upside, equities research analysts clearly believe Edgewise Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Do insiders & institutionals have more ownership in EWTX or NUVL? 97.3% of Nuvalent shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 10.2% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryEdgewise Therapeutics beats Nuvalent on 8 of the 13 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56B$3.09B$5.83B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-9.5521.1631.1625.99Price / SalesN/A396.94474.86122.97Price / CashN/A43.0937.1558.38Price / Book2.658.069.116.38Net Income-$133.81M-$54.72M$3.26B$265.56M7 Day Performance4.59%2.52%2.06%1.89%1 Month Performance9.30%7.54%5.08%1.23%1 Year Performance-24.46%13.01%31.26%21.10% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.3662 of 5 stars$14.80+1.2%$40.55+174.0%-30.2%$1.56BN/A-9.5560Analyst ForecastNUVLNuvalent3.284 of 5 stars$74.95+1.1%$119.60+59.6%-10.9%$5.32BN/A-15.3040News CoverageAnalyst ForecastInsider TradeABVXAbivax2.877 of 5 stars$69.00-1.6%$92.33+33.8%+544.4%$5.30BN/A0.0061Short Interest ↑AXSMAxsome Therapeutics4.8104 of 5 stars$103.96-0.8%$178.00+71.2%+33.2%$5.23B$385.69M-20.50380News CoveragePositive NewsCRSPCRISPR Therapeutics3.7962 of 5 stars$55.41+0.7%$71.60+29.2%+5.7%$5.00B$37.31M-10.20460MRUSMerus2.3158 of 5 stars$64.60+0.9%$88.50+37.0%+24.4%$4.84B$36.13M-11.7537News CoveragePositive NewsVKTXViking Therapeutics4.0243 of 5 stars$38.20+0.8%$86.92+127.6%-60.4%$4.26BN/A-24.9620Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3598 of 5 stars$26.39-1.2%$46.25+75.3%+14.8%$4.24B$329M71.32290Positive NewsACADACADIA Pharmaceuticals3.9511 of 5 stars$24.82+0.9%$28.88+16.3%+55.6%$4.15B$957.80M18.66510Insider TradeCYTKCytokinetics3.6123 of 5 stars$33.23-2.6%$70.69+112.7%-32.8%$4.08B$18.47M-6.52250News CoverageAKROAkero Therapeutics4.0272 of 5 stars$48.28-4.3%$81.57+69.0%+83.3%$4.02BN/A-24.1430News CoveragePositive News Related Companies and Tools Related Companies Nuvalent Competitors Abivax Competitors Axsome Therapeutics Competitors CRISPR Therapeutics Competitors Merus Competitors Viking Therapeutics Competitors TG Therapeutics Competitors ACADIA Pharmaceuticals Competitors Cytokinetics Competitors Akero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access